The membrane protein tyrosine phosphatase receptor U (PTPRU) has been shown to function as a negative regulator of adhesion and proliferation in certain cancer cell types, primarily through its dephosphorylation of β-catenin and inhibition of subsequent downstream signaling. In the present study, we set out to characterize the role of PTPRU in glioma and found that, while the expression of full-length PTPRU protein is low in these tumors, a number of non-full-length PTPRU isoforms are highly expressed. Among these isoforms, one in particular is localized to the nucleus, and its expression is increased in glioma tissues in a manner that positively correlates with malignancy grade. Short hairpin RNA knockdown of endogenous PTPRU in human and rat glioma cell lines suppressed proliferation, survival, invasion, migration, adhesion and vasculogenic tube formation in vitro, as well as intracranial tumor progression in vivo. In addition, knocking down PTPRU reduced tyrosine phosphorylation (pY) and transcriptional activity of β-catenin, and we were able to specifically rescue the cell migration defect by expressing a LEF1-β-catenin fusion protein in PTPRUdepleted cells. PTPRU knockdown also led to increased tyrosine pY of the E3 ubiquitin ligase c-Cbl and to the destabilization of several focal adhesion proteins. Taken together, our findings demonstrate that endogenous PTPRU promote glioma progression through their effect on β-catenin and focal adhesion signaling.
Introduction
Malignant gliomas are an uncommon, but exceedingly lethal tumor type. They are extremely proliferative and invasive, display highly aberrant vascularization and are resistant to traditional radiotherapy and chemotherapy regimens, making them difficult to remove completely with the usual standard of care (1) . Not surprisingly then, malignant gliomas have one of the worst prognosis of any brain tumor, with a 5-year survival rate of ~5% (2) . Investigations into the molecular pathology of gliomas are therefore urgently needed, in order to develop new therapeutic strategies and improve patient outcomes.
Protein tyrosine phosphatase receptor U (PTPRU, also known as PCP-2 or PTPλ), together with PTPRK, PTPRM and PTPRT, constitute the R2B subfamily of receptor protein tyrosine phosphatases (RPTPs), which are involved in cell adhesion and commonly function as tumor suppressors (3) (4) (5) (6) (7) . Along with their counterpart receptor tyrosine kinases, RPTPs are also known to be involved in glioma biology; however, the role of the latter is not nearly as well understood (3, 8) . Among the R2B phosphatases, PTPRK has been shown to hamper tyrosine phosphorylation (pY) and nuclear accumulation of β-catenin and to promote membrane relocalization of E-cadherin/β-catenin complexes along cell-cell contacts (9) . Through this mechanism, PTPRK has been shown to hinder the proliferation and motility of melanoma and breast cancer cells, and its expression is consistently low in these cancers (9) (10) (11) . In addition, mutant forms of PTPRK resulting from deletion or missense mutations identified from glioma samples abrogate the tumor suppressive effect of wild-type PTPRK (12) . Another R2B subfamily member, PTPRM, can impede glioma cell motility by affecting cell-cell adhesion and by downregulating pY of the phospholipase PLCγ1. It also inhibits the proliferation and motility of breast cancer cells by decreasing ERK and JNK pY levels (7, 13, 14) . PTPRT is thought to inhibit colon cancer growth by downregulating STAT3 and paxillin pY, and mutation of its extracellular domain may promote metastasis by impairing homophilic cell aggregation (15) (16) (17) . Similar to PTPRK, PTPRU binds β-catenin to negatively regulate its pY and transcriptional activity, thus inhibiting the growth and migration of colon cancer cells (6) . Decreased expression of PTPRU has also been observed in melanoma (11) .
In addition to genetic mutations and expression defects, aberrant proteolytic cleavage of R2B RPTPs has also been shown to promote tumor progression. For example, intracellular cleavage of PTPRK and PTPRM, by getting rid of extracellular domains involved in cell adhesion, leads to increased cell motility (18, 19) . The cleavage also creates intracellular RPTP fragments that can translocate to the nucleus and activate oncogenic signaling pathways, possibly through β-catenin (19, 20) . Glioma have been found to harbor highly cleaved forms of PTPRM, and knocking down all of these PTPRM fragments inhibits the growth and motility of glioma cells (19, 21) . Together, these findings suggest a pro-oncogenic role for the non-full-length R2B RPTP fragments associated with cancer cells.
Compared with other members of the R2B subfamily, the function and mechanism of PTPRU in cancer remains poorly characterized to date. PTPRU is also the most distant member of its subfamily, and has been shown to have some distinct biological functions (7) . In the present study, we identified a non-full-length PTPRU isoform that is primarily localized to the nucleus and greatly increased in glioma. We also showed that knocking down PTPRU expression inhibits glioma growth and motility by reducing β-catenin pY and destabilizing focal adhesion (FA) proteins.
Materials and methods

Cell culture
Human glioma cell lines U87, U251, U373, A172 and SHG-44, and the human breast cancer cell line MCF-7 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). Rat glioma cell line C6 and rat primary glia were cultured in DMEM/F12 (Invitrogen) with 10% FBS. Human non-small cell lung cancer cell lines 95D, A549, H460, H1299 and SPC-A1, and the human colorectal cancer cell lines DLD1 and SW480 were cultured in RPMI 1640 (Invitrogen) with 10% FBS. All cell lines were obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and authenticated by DNA fingerprinting using primer sets DXS52, Apo-B, MD17S5 and D2S44. All cell lines were maintained under standard cell culture conditions at 37°C and 5% CO 2 and passaged for <2 months after resurrection.
Reagents
The following primary antibodies were used in this study: PTPRU (HPC039832) (Sigma-Aldrich, St Louis, MO), PTPλ (ab13223, PTPRU antibody for knockdown validation) (Abcam, Cambridge, UK), β-catenin (610153), c-Cbl (610441), EGFR (610016), FAK (610087) (BD Biosciences, San Jose, CA), caspase-3 Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FA, focal adhesion; FBS, fetal bovine serum; mRNA, messenger RNA; MTT, 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide; PTPRU, protein tyrosine phosphatase receptor U; pY, tyrosine phosphorylation; RPTP, receptor protein tyrosine phosphatase; shRNA, short hairpin RNA.
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(9662), c-Myc (9402), Dnmt1 (5032), Histone H3 (4499), LEF1 (2230), p-Tyr-102 (9416), survivin (2802), TCF4 (2569) (Cell Signaling Technology, Beverly, MA), CD31 (BS1574), Ki-67 (BS1454), p27 Kip1 (BS3714), PYK2 (BS1420), paxillin (BS1288), vimentin (BS1776) (Bioworld Technology, Nanjing, China), cyclin B1 (BA0766), cyclin D1 (BA0770), lamin B (BA1228), VE-cadherin (BA3032) (Boster, Wuhan, China), GFAP (60190-1-Ig), ubiquitin (10201-2-AP) (ProteinTech Group, Wuhan, China) and GAPDH (KC-5G5) (Kangchen, Shanghai, China). The following secondary antibodies were used: horseradish peroxidase-conjugated anti-mouse (7076) and anti-rabbit (7074) (Cell Signaling Technology), and Alexa Fluor 546 goat anti-rabbit (A-11035) (Invitrogen). The following reagents were used: lentiviral vectors pLKD-CMV-GFP-U6-shRNA and pLOV-CMV-eGFP (Neuron Biotech, Shanghai, China), lipofectamine 2000 (Invitrogen), propidium iodide (Sigma-Aldrich), protease inhibitor cocktail, RNase A (Thermo Scientific, Waltham, MA), 24-well cell culture inserts (8 μm pore), 24-well matrigel invasion chamber (8 μm pore), matrigel matrix, collagen I from rat tail (BD Biosciences), endothelial basal medium EBM-2 (Lonza, Basel, Switzerland), phosphatase inhibitor (Sangon, Shanghai, China), TOP-FLASH reporter construct (Genomeditech, Shanghai, China), RT M-MLV, dualluciferase reporter assay system, pRL-CMV vector (Promega, Madison, WI), SYBR Premix Ex Taq (Takara, Dalian, China), cell lysis buffer for Western and IP, hematoxylin and eosin staining kit, nuclear and cytoplasmic protein extraction kit, protein G agarose and PMSF (Beyotime, Nantong, China).
Tissue samples
One healthy brain sample and 30 glioma samples, which had been used for previous studies, were obtained from the glioma tissue bank of Department of Neurosurgery of Huashan Hospital, Fudan University, in compliance with the National Regulation of Clinical Sampling in China. Tissues were diagnosed and graded before they were stored.
Lentivirus-mediated gene transduction
Short hairpin RNAs (shRNAs) targeting human and rat PTPRU were inserted into the lentiviral vector pLKD-CMV-GFP-U6-shRNA. A human LEF1/CTN fusion gene [which encodes human LEF1 lacking the N-terminal β-catenin binding domain (aa 2-56) fused to the transcriptional activation domain of human CTNNB1 (aa 650-781), ref. (22)] was generated by PCR amplification and inserted into the lentiviral vector pLOV-CMV-eGFP. Lentiviruses encoding targeted shRNA plasmids, the scrambled shRNA plasmid and the human LEF1/CTN fusion gene were produced by Neuron Biotech. shRNA sequences were as follows: shPTPRU (human), CCGG GGAGATGATCCGCA TTGA TCCCTCGAG GGATCAATGCGGA TCAT CTCCTTTTTTG; shPTPRU-R1 (rat), CCGGGCATTG ACCCTCAGAGTAACTCTCGAGAG TTACTC TGAGGGTC AATGCTTTTTTG; shPTPRU-R2 (rat), CCGGGGTGG AGACC ATGGATCAATACT CGAGTATTGATCCA TGGTCTCCACCTTTTTTG; scrambled shRNA, CCGGTTCTC CGAACGTGTCACGTTTCAAGAGAA CGTGACACGTTCGGAGAATTTTTTG.
Western blot
After collection, cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 2 mM ethylenediaminetetraacetic acid, 1% NP-40, 150 mM NaCl, 1 mg/ml sodium dodecyl sulfate, 0.25 mg/ml sodium deoxycholate) supplemented with phenylmethylsulfonyl fluoride, phosphatase inhibitor and protease inhibitor cocktail. Western blot was carried out as described previously (23) . To analyze the relative protein level of interest, the band grayscale of interested protein and loading control was quantified using the Adobe Photoshop software and the ratio of interested protein to loading control was calculated.
Quantitative real-time PCR RNA was extracted, reverse transcribed and analyzed by quantitative realtime PCR as described previously . The following sets of primers were used for PCR: human PTPRU, 5′-GAGTGAAACTGCACCCGATG-3′, 5′-CA CACCATACGCCAGAAGTCAT-3′; rat PTPRU, 5′-ACTGCGTGAAG ACCCTCTGTT-3′, 5′-TACTCTGAGGGTCAATGCGGA-3′; human glyceraldehyde 3-phosphate dehydrogenase, 5′-AAGGTGAAGGTCGGAGTCAAC-3′, 5′-GGGGTCATTGATGGCAACAATA-3′; rat glyceraldehyde 3-phosphate dehydrogenase, 5′-CCCCAATGTATCCGTTGTG-3′, 5′-CTCAGTGTAGCCC AGGATGC-3′; human FAK, 5′-TGGTGCAATGGAGCGAGTATT-3′, 5′-CA GTGAACCTCCTCTGACCG-3′; human PXN, 5′-CTGCTGGAACTGAAC GCTGTA-3′, 5′-GGGGCTGTTAGTCTCTGGGA-3′.
Immunofluorescence
Cells were plated onto glass coverslips in culture medium for 24 h, then fixed with 4% paraformaldehyde. Cells and brain sections were incubated with blocking buffer (3% bovine serum albumin and 0.1% Triton in phosphate-buffered saline) for 1 h, stained with antibodies overnight, then incubated with Alexa-546-conjugated secondary antibody and Hoechst 33342 for 2 h. Fluorescent signals were observed with a Nikon eclipse Ti-S inverted microscope.
Colony formation assay
Colony formation assays were performed as described previously (23) MTT assay 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays were performed as described previously (23) .
Flow cytometry assay
Cell cycle distribution and apoptosis were determined by flow cytometry, as described previously (23) . Data were analyzed by FlowJo software.
Transwell invasion and migration assay
For the cell invasion assay, matrigel invasion chambers (8 μm, 24-well cell culture inserts) were used according to the manufacturer's protocol. Briefly, 5 × 10 4 cells were resuspended in 500 μl DMEM and added to the upper chamber; 500 μl DMEM with 10% FBS were used in the lower chamber as a chemoattractant. After 22 h in culture, cells on the upper surface of the membrane were removed using a cotton swab and the membranes were stained with crystal violet. Cell numbers were determined by averaging cell counts from nine separate 10× (U87 and U251) or 20× (C6) fields.
For the cell migration assay, 5 × 10 4 cells were resuspended in 200 μl DMEM and added to the upper chambers of the 24-well cell culture inserts without matrigel (8 μm); 500 μl DMEM with 10% FBS were used in the lower chamber. After 4 h in culture, cells on the upper surface of the membrane were removed and the membranes were stained with crystal violet.
Cell adhesion assay
For the cell-matrix adhesion assay, cells were detached with 10 mM ethylenediaminetetraacetic acid in DMEM, washed twice with DMEM and resuspended in DMEM with 0.1% bovine serum albumin at a concentration of 2 × 10 5 cells/ ml. A total of 100 μl of cell suspension was then added to each well of 96-well plates precoated with collagen I solution (1.6 μg/well in D-Hank's), and the plates were incubated for 20 min at 37°C. Non-adherent cells were removed by washing four times with DMEM. Next, 100 μl DMEM with 10% FBS was added and the cells were incubated for another 4 h. Adherent cells were then quantified by MTT assay.
Vasculogenic tube formation assay
Vasculogenic tube formation assays were performed as described previously (24) . Briefly, 3 × 10 4 U87, U251 and C6 cells resuspended in 500 μl EBM-2 with 2% FBS were plated onto 24-well cell culture plates precoated with 100 μl matrigel, and incubated for 22 h at 37°C. Tube loops (closed areas surrounded by cells) were quantified with Wimasis Image Analysis software, by averaging the number of loops from four separate 20× fields.
Immunoprecipitation
Cells were washed with phosphate-buffered saline and lysed on ice in cell lysis buffer for western and immunoprecipitation. Lysates were adjusted to have equal protein concentrations and incubated with mouse IgG and protein G agarose for 1 h at 4°C to reduce unspecific binding. Supernatants were incubated with antibodies overnight, and with additional protein G agarose for 2 h at 4°C. Precipitates were washed four times with lysis buffer before sodium dodecyl sulfate-polyacrylamide gel electrophoresis loading buffer was added.
Luciferase reporter gene assay
Luciferase reporter gene assays were conducted using a dual-luciferase reporter assay system according to the manufacturer's protocol. Cells were cotransfected with the TOP-FLASH luciferase reporter plasmid and the Renilla luciferase plasmid pRL-CMV using Lipofectamine 2000. Light units were measured using the BioTek synergy 2 microplate reader. Firefly luciferase activity was divided by Renilla luciferase activity to assess transfection efficiency.
In vivo tumor model
For intracranial implantation, BALB/c athymic nude male mice (5 weeks old, n = 6 for U87 and n = 5 for C6) (Shanghai Lab, Animal Research Center, Shanghai, China) were anesthetized, maintained and fixed with a stereotactic device. An incision was made, and a burr hole was drilled into the skull 2 mm to the left and 0.5 mm anterior to the bregma. U87 and C6 cells (1 × 10 5 cells/3 μl DMEM) infected with shPTPRU constructs or with scrambled shRNA were injected into the left striatum of the brain to a depth of 3 mm at a rate of 0.5 μl/ min. The craniotomy was then covered with dental cement and the incision was closed with sutures. Twenty-seven and 15 days after implantation, some mice in control groups bearing U87 and C6 xenografts were in articulo mortis, respectively, and all mice were anesthetized and perfused with 4% paraformaldehyde. Their brains were removed and 20 μm cryosections were cut and used for hematoxylin and eosin staining and immunofluorescence. Tumor volume was calculated by measuring the section with the largest tumor area PTPRU for glioma growth and motility 
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and applying the formula: Volume = length × width 2 × 0.5 (25) . All procedures were carried out in accordance with the ethical standards relating to studies on animals of the East China University of Science and Technology.
Statistical analysis
Intracranial tumor volumes are expressed as mean ± standard error of the mean. All other values are expressed as mean ± SD. Student's t-test was used to determine significant differences between groups, with statistical significance defined as P < 0.05.
Results
PTPRU expression in multiple cancer cell lines
Consistent with previously reported findings and with its role as a tumor suppressor, we found that the level of the 200 kDa fulllength PTPRU protein (PTPRU-FL) is relatively low in several cancer cell lines, including breast cancer, non-small cell lung cancer and glioma cell lines (6,11). However, a number of non-full-length PTPRU fragments with lower molecular weights were observed in our experimental cell lines ( Figure 1A and B) . In addition, C6 cell line has lower level of PTPRU-FL but higher levels of several PTPRU fragments compared with those in primary rat glia ( Figure 1B) . A 130 kDa fragment was primarily localized to the nucleus, whereas bands of various other molecular weights were found in the membrane or cytoplasm of human glioma cell lines U87 and U251, and the rat glioma cell line C6 ( Figure 1C ). We next looked at the levels of PTPRU-FL and PTPRU fragments in human glioma tissues of varying grades. Although the sample sizes were too small to achieve significant differences between each pair of grades, we nevertheless observed that 130 kDa fragment levels were relatively high in glioma tissues and increased along with the tumor grade. Contrastingly, levels of PTPRU-FL were significantly higher in lower grades (I-II) than in grade IV samples ( Figure 1D ). These results suggest that PTPRU fragments are common to various types of cancers, and they may be involved in the malignant progression of glioma. 
PTPRU for glioma growth and motility
PTPRU is required for proliferation and survival of glioma cells
To investigate the role of endogenous PTPRU in glioma, we knocked down its expression by infecting human U87 and U251 cells with lentivirus encoding shRNA-targeting human PTPRU (shPTPRU), and rat C6 cells with two shRNAs targeting rat PTPRU (shPTPRU-R1 and shPTPRU-R2). Levels of PTPRU messenger RNA (mRNA) and protein were both significantly reduced in the shPTPRU groups in all three cell lines compared with those in the non-transfected and scrambled shRNA (control) groups (Figure 2A and B and Supplementary Figure S1A ,B,D,E, available at Carcinogenesis Online). In addition, levels of all PTPRU variants (including PTPRU-FL as well as 160, 130, 115, 80 kDa fragments) were significantly downregulated in the knockdown groups, thus confirming the specificity of our PTPRU antibody (Figure 2A) . Consistent with the results presented in the Human Protein Atlas (26), PTPRU immunofluorescence was mainly localized to the nucleus of U87 and U251 cells, and its intensity was reduced following PTPRU knockdown (Supplementary Figure S1C , available at Carcinogenesis Online).
Knockdown of PTPRU decreased the survival and proliferation capacities of U87, U251 and C6 cells, as revealed by colony formation and MTT assays, respectively ( Figure 2C and D) . Moreover, flow cytometry indicated that PTPRU depletion stalled cell cycle progression in the G 0 /G 1 phase in U87 and C6 cells, and in the G 2 /M phase in U251 cells ( Figure 2E ). PTPRU knockdown also induced apoptosis in U87 and U251 cells, but not in C6 cells (Supplementary Figure S2A , available at Carcinogenesis Online and data not shown). Consistent with these findings, expression of the proliferation marker Ki-67 was decreased and that of the apoptosis marker cleaved caspase-3 was increased in U87 and U251 cells expressing shPTPRU ( Figure 2F and Supplementary Figure  S2B , available at Carcinogenesis Online). In addition, levels of the positive cell cycle regulators cyclin D1, cyclin B1 and survivin, were obviously reduced in shPTPRU U87, U251 and C6 cells; whereas expression of the negative cell cycle regulator p27 Kip1 was increased ( Figure 2G ). Due to the complexity posed by the presence of several unidentified PTPRU fragments, no gain-of-function experiments were carried out in the present study. Together, these findings suggest that knocking down PTPRU suppresses proliferation and survival of glioma cells in vitro by arresting cell cycle progression and inducing apoptosis.
PTPRU is required for glioma cell motility
We noticed that U87 and U251 cells expressing shPTPRU lost their typical elongated, spindle-shaped morphology to become plump and flattened, whereas shPTPRU C6 cells developed shorter cell bodies with longer, fine and tapering processes (Supplementary Figure S3A , available at Carcinogenesis Online). These morphological changes suggested that PTPRU might be involved in regulating glioma cell motility. Transwell invasion and migration assays, together with a cellextracellular matrix adhesion assay, respectively showed that depleting PTPRU suppresses invasion, migration and adhesion of U87, U251 and C6 cells (Figure 3A-D) . A second cell adhesion assay not involving collagen I coating showed that control cells adhered more strongly to an uncoated culture surface than shPTPRU cells, at any given point during the experimental period, suggesting that the PTPRU-mediated adhesion is independent of extracellular matrix such as collagen I (Supplementary Figure S3B , available at Carcinogenesis Online). In addition, wound-healing assays demonstrated that the migration ability of glioma cells was not significantly affected by PTPRU knockdown if a chemoattractant gradient did not exist (Supplementary Figure S3C , available at Carcinogenesis Online). Since aggressive glioma cells themselves have the ability to form vessel-like structures to facilitate their infiltrative growth (27), we next carried out a vasculogenic tube formation assay, which showed that shPTPRU glioma cells formed markedly fewer tubes than control cells ( Figure 3E and F) . Consistent with these observed changes, we noticed a reduction in the expression of several protein markers, including FA proteins FA kinase (FAK), proline-rich tyrosine kinase 2 (PYK2) and paxillin, the vasculogenic mimicry-associated protein VE-cadherin and the mesenchymal cell marker vimentin ( Figure 3G ). These results indicate that PTPRU knockdown inhibits glioma cell motility in vitro.
PTPRU is required for in vivo glioma progression
To characterize the in vivo role of PTPRU in glioma progression, we intracranially injected shPTPRU U87 and C6 cells to induce tumors in the brains of nude mice. Twenty-seven days postinjection, mean tumor volume in control U87-treated mice (29.487 ± 6.457 mm Figure 4A and B) . In addition, body weights of mice in control groups were lower than their shPTPRU groups at the end of the experiment, indicating that control U87-and C6-induced tumors undermined the health of their hosts earlier than shPTPRU tumors (Supplementary Figure S4 , available at Carcinogenesis Online). Furthermore, CD31 immunostaining revealed that there were obviously less microvessels in shPTPRU U87-and C6-induced tumors than in control tumors ( Figure 4C ). These observations suggest that PTPRU is required for in vivo glioma progression.
PTPRU regulates tyrosine pY and transcriptional activity of β-catenin in glioma cells
Activation of β-catenin has been shown to be essential for glioma cell proliferation and motility. PTPRU-FL is able to dephosphorylate β-catenin, thereby negatively regulating its transcriptional activity (6,28,29) . To investigate the effects of PTPRU knockdown on downstream signaling, we used immunoprecipitation experiments to assess β-catenin pY levels and detect PTPRU-β-catenin interactions in glioma cells. We found that pY of β-catenin was obviously reduced in shPTPRU-treated U87 and U251 cells, whereas total protein pY was not altered ( Figure 5A ). Moreover, PTPRU knockdown did not affect β-catenin stability or nuclear accumulation ( Figure 5B ). The shPTPRUinduced reduction in β-catenin pY took place primarily in the nucleus, thus inhibiting the interaction between β-catenin and TCF4, and leading to the inactivation of the β-catenin/TCF/LEF1 transcription complex, as measured by luciferase reporter activity (Figure 5B-D) . Transcription complex inactivation was further confirmed by the finding that the expression levels of several β-catenin signaling target genes were greatly reduced, including cyclin D1, survivin, vimentin, c-Myc, LEF1, Dnmt1 and EGFR (30) (31) (32) (33) (34) (35) (36) (Figures 2G,3G and 5E) . A previous functional study of PTPRU-FL had been carried out with the colon cancer cell line SW480 (6); we therefore compared the transcriptional activity of β-catenin in glioma (U87 and U251) and colon cancer (DLD1 and SW480) cell lines. We found that β-catenin activity was significantly higher in colon cancer cells than in glioma cells, particularly in SW480 cells (Supplementary Figure S5 , available at Carcinogenesis Online). To explore the role of PTPRU-dependent β-catenin transcriptional activity in glioma cell progression, we introduced a LEF1-β-catenin fusion protein (LEF1/CTN) with the ability to activate the TCF/LEF1 luciferase reporter into PTPRU-depleted U87 and U251 cells (22) . The LEF1/CTN fusion protein was able to reactivate β-catenin/TCF/ LEF1 complex-mediated luciferase reporter activity, and also to rescue migration defects in shPTPRU cells, but it had no effect on proliferation ( Figure 5F -H and data not shown). Taken together, these results show that endogenous PTPRU positively regulates β-catenin pY and transcriptional activity, which are required for glioma cell motility.
PTPRU knockdown downregulates FA protein expression via the ubiquitin-proteasome pathway
Knocking down PTPRU in glioma cells had no effect on the expression of FAK and paxillin mRNAs, but significantly reduced their The number of migrating cells, counted and averaged over nine randomly selected fields, is quantified on the right-hand panel. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (A, E, F and cytoplasmic in B), lamin B (nuclear in B) and histone H3 (nuclear in C) were used as loading controls. *P < 0.05. protein levels. Addition of the proteasome inhibitor MG132 blocked this reduction ( Figures 3G and 6 A-C) . Moreover, PTPRU knockdown increased ubiquitination, but did not alter pY of FAK ( Figure 6D ). These results suggest that PTPRU knockdown had no effect on FA protein transcription, but instead affected their stability. Proteolysis of FA proteins is mediated by enzymes such as the ubiquitin ligase c-Cbl (37) . Here, we found that knocking down PTPRU led to increased c-Cbl pY and promoted the binding of c-Cbl to FAK, thus facilitating its ubiquitination ( Figure 6E ). These findings demonstrate that knocking down PTPRU destabilizes FA proteins via the ubiquitin-proteasome pathway.
Discussion
Accumulating evidence has revealed that R2B subfamily RPTPs play various tumor suppressive roles, and that their mutations, decreased expressions or protein modifications can promote tumor progression (6, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The present study adds to this body of evidence, by demonstrating that endogenous PTPRU are required for glioma growth and motility, likely by activating β-catenin signaling and maintaining FA protein stability.
The expression patterns and regulatory mechanisms of PTPRU differ somewhat from those of other R2B RPTPs. As reported in the REMBRANDT knowledge base (https://caintegrator.nci.nih.gov/ rembrandt/) (38), PTPRU mRNA is not typically downregulated (≥2-fold) in glioma samples, only in 13.41% of cases, and its expression does not correlate with patient survival probability. On the other hand, mRNA downregulation in glioma is much more common for the other three R2B RPTPs (44.02% for PTPRM, 37.32% for PTPRK and 69.10% for PTPRT), and levels have been found to correlate with survival probability. It is important to note, however, that PTPRU mRNA levels may not directly correspond to PTPRU protein levels, as the latter may rise due to changes in translation efficiency or protein stability. In the present study, we found that levels of the tumor suppressor PTPRU-FL were significantly lower than those of nonfull-length PTPRU protein fragments in glioma cells and samples. This imbalanced protein expression could not be attributed to furinmediated proteolytic cleavage, a mechanism shared by both PTPRM and PTPRK (19, 20) , since treatment with furin inhibitor I (Decanoyl-RVKR-CMK) had no effect on the levels of PTPRU fragments (data not shown). The finding that knocking down the expression of all PTPRU fragments suppressed glioma cell growth and motility does however resemble results obtained with PTPRM (19, 21) , suggesting that some R2B RPTP fragments are essential to glioma progression.
Although malignant gliomas rarely metastasize to extracranial organs, their highly infiltrative behavior makes them difficult to eradicate and lead to poor disease prognosis. Glioma infiltration is critically dependent on the dynamic process of FA complex formation and turnover (39) , as evidenced by the finding that inhibiting FA protein expression or activity significantly impedes glioma cell motility (40). We found that PTPRU knockdown promotes the proteolysis of various FA proteins (FAK, PYK2 and paxillin) and inhibits a number of glioma motility-associated characteristics, such as polarized cell morphology, invasion, migration, adhesion and vasculogenic mimicry. FA protein proteolysis is catalyzed by several enzymes, including c-Cbl and USP2a, which respectively ubiquitinate and deubiquitinate FA proteins (37, 41) , as well as calpains and caspases, which directly cleave FA proteins (42) (43) (44) (45) . Our results showed that PTPRU knockdown leads to c-Cbl activation and to increased association between c-Cbl and FAK. However, it remains to be determined how PTPRU regulates c-Cbl pY and whether other enzymes also account for the proteolysis of FA proteins in gliomas.
PTPRU knockdown was also found to inhibit β-catenin pY and transcriptional activity, thereby downregulating the expression of several target genes of β-catenin signaling, including LEF1. We were able to rescue some of the motility defects by coexpressing a LEF1/β-catenin fusion protein together with shPTPRU, suggesting that β-catenin signaling is directly involved in glioma cell motility. β-catenin activity depends on its levels of pY, which are sophisticatedly regulated by different proteins in distinct subcellular location. Specifically, pY of membrane or cytoplasmic β-catenin promotes its nuclear accumulation and transcriptional activation, whereas pY of nuclear β-catenin affects its activity, but not its protein levels or cellular distribution (46) (47) (48) . Herein, we showed that PTPRU knockdown specifically inhibits the pY of nuclear β-catenin in U251 cells. Characterization of the different PTPRU isoforms and their functions will help further our understanding of PTPRU/β-catenin interaction.
Our findings highlight a discrepancy between the role of PTPRU in glioma, and the function of PTPRU-FL as a negative regulator of β-catenin activity and tumor progression in SW480 colon cancer cells (6) . Three potential reasons might explain this dichotomy. First, a change in subcellular localization may alter the effect of an enzyme on its substrate. For example, membrane PTK6 enhances β-catenin activity, whereas nuclear PTK6 attenuates it (49) . Second, we showed that PTPRU-FL is not the only isoform that associates with β-catenin in the nucleus, and the functions of the various fragments may differ from those of the full-length form. The observation that chemical or shRNA inhibition of endogenous PTPRM suppresses growth and migration supports this hypothesis (19) . Third, transcriptional activation of β-catenin does not only involve the modification of the protein itself, but also the coordinated action of various molecules across the entire signaling network. This might explain why β-catenin transcriptional activity varies significantly between glioma and colon cancer cells, particularly between U251 and SW480 cell lines.
In summary, we show here that glioma cells present low levels of PTPRU-FL protein, but high levels of various PTPRU fragments. Presence of these non-full-length fragments is essential for glioma to retain their proliferative and infiltrative capacities. We also demonstrated that PTPRU knockdown-induced inhibition of glioma cell motility is mediated at least in part through β-catenin signaling inactivation and ubiquitin ligase-mediated degradation of FA proteins. Thus, our findings provide novel insight into the mechanisms that can transform a RPTP from a tumor suppressor to a tumor-promoting agent.
Supplementary material
Supplementary Figures S1-S5 can be found at http://carcin.oxfordjournals.org/.
